徐芬;周洲;
XU Fen;ZHOU Zhou;Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,National Center for Cardiovascular Diseases;

• 1:国家心血管病中心中国医学科学院阜外医院实验诊断中心

摘要(Abstract)：

美国心脏协会、美国心脏病学会和美国心力衰竭协会联合发布了《2022年AHA/ACC/HFSA心力衰竭管理指南》。该指南倡导心力衰竭防治并重，强调基于利钠肽筛查的一级预防对A期(心力衰竭风险期)或B期(心力衰竭前期)患者至关重要；推荐C期(心力衰竭期)患者应接受多学科团队管理，尽早使用包括钠-葡萄糖协同转运蛋白2抑制剂的“基础四联疗法”;并推荐将希望延长生存期的D期(心力衰竭晚期)患者及时转诊至心力衰竭专科团队，以评估晚期心力衰竭治疗的适用性。
Recently, 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure has been published. It advocates to pay equal attention to the prevention and treatment of heart failure; and emphasizes that primary prevention based on natriuretic peptides screening is essential for patients at risk for heart failure or with pre-heart failure. Furthermore, it recommends that patients with symptomatic heart failure should receive care from a multidisciplinary team to facilitate the implementation of “basic quadruple therapy” including sodium glucose cotransporter 2 inhibitors; and that patients with advanced heart failure who wish to prolong their survival should be timely referral for heart failure specialty care and assess suitability for advanced heart failure therapies.

关键词(KeyWords)： 心力衰竭;预防;治疗;利钠肽;钠-葡萄糖协同转运蛋白2抑制剂
heart failure;prevention;treatment;natriuretic peptides;sodium-glucose cotransporter 2 inhibitor

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 徐芬;周洲;
XU Fen;ZHOU Zhou;Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,National Center for Cardiovascular Diseases;

参考文献(References)：

• [1] Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2022,145:e895-e1032.
• [2] 《心力衰竭通用定义和分类》将开启心力衰竭诊疗的标准化进程[J].协和医学杂志，2021,12:621- 623.
• [3] McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42:3599- 3726.
• [4] Faggiano P,Bernardi N,Calvi E,et al.Stage A Heart Failure:Modern Strategies for an Effective Prevention[J].Heart Fail Clin,2021,17:167- 177.
• [5] Redfield MM.Strategies to screen for stage B as a heart failure prevention intervention[J].Heart Fail Clin,2012,8:285- 296.
• [6] Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62:e147-e239.
• [7] Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136:e137-e161.
• [8] Arnett DK,Blumenthal RS,Albert MA,et al.2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Circulation,2019,140:e596-e646.
• [9] Ledwidge M,Gallagher J,Conlon C,et al.Natriuretic peptide-based screening and collaborative care for heart failure:the STOP-HF randomized trial[J].JAMA,2013,310:66- 74.
• [10] Huelsmann M,Neuhold S,Resl M,et al.PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease):a prospective randomized controlled trial[J].J Am Coll Cardiol,2013,62:1365- 1372.
• [11] Suthahar N,Lau ES,Blaha MJ,et al.Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers with Incident Heart Failure[J].J Am Coll Cardiol,2020,76:1455- 1465.
• [12] Bozkurt B.It Is Time to Screen for Heart Failure:Why and How?[J].JACC Heart Fail,2022,10:598- 600.
• [13] McMurray JJV,Solomon SD,Inzucchi SE,et al.Dapagliflozin in patients with heart failure and reduced ejection fraction[J].N Engl J Med,2019,381:1995- 2008.
• [14] Packer M,Anker SD,Butler J,et al.Cardiovascular and renal outcomes with empagliflozin in heart failure[J].N Engl J Med,2020,383:1413- 1424.
• [15] Zannad F,Ferreira JP,Pocock SJ,et al.SGLT2 inhibitors in patients with heart failure with reduced ejection fraction:a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J].Lancet,2020,396:819- 829.
• [16] Sharma A,Verma S,Bhatt DL,et al.Optimizing Foundational Therapies in Patients With HFrEF:How Do We Translate These Findings Into Clinical Care?[J].JACC Basic Transl Sci,2022,7:504- 517.